What is Amondys 45 (sarepta)?
Amondys 45 is a brand name for eteplirsen, a medicine made by Sarepta Therapeutics. It is used for Duchenne muscular dystrophy (DMD) in a specific genetic subset: people who have a confirmed mutation amenable to exon 45 skipping (the drug is designed to help the body “skip” exon 45 during dystrophin mRNA processing) [1].
Who can use it, and how is eligibility determined?
Use depends on having DMD with a mutation that is amenable to exon 45 skipping. In practice, clinicians confirm eligibility with genetic testing to identify the specific dystrophin gene mutation pattern that matches exon 45 skipping criteria [1].
How does it work?
Eteplirsen targets the DMD gene transcript so that exon 45 is skipped during mRNA splicing. This can allow production of a shorter dystrophin protein than normal, which is expected to help muscle cells by partially restoring dystrophin production for people in the exon 45 skipping subset [1].
How is it given?
Amondys 45 (eteplirsen) is administered as an intravenous infusion (given through a vein) [1].
What should patients ask about before starting?
Common practical questions include:
- Whether their mutation is truly amenable to exon 45 skipping based on their test results.
- The expected monitoring plan while on IV infusions.
- How clinicians will judge benefit over time (for example, through dystrophin-related measures and functional outcomes) [1].
Are there alternatives to Amondys 45 for DMD?
Yes. For DMD, other therapies exist that target different exons (and therefore different mutation types). Which option fits depends on the individual’s mutation and eligibility for exon-skipping approaches [1].
---
Sources
[1] https://www.sareptatherapeutics.com/patients/amondys-45